Karolinska Institute Endowment

Investment Strategy

The Karolinska Institute manages combined endowment and foundation assets of approximately $1.0 billion as of June 30, 2024. Located in Stockholm, the Karolinska Institute is one of the world’s leading medical universities and is globally recognized as the institution whose Nobel Assembly selects the laureate for the Nobel Prize in Physiology or Medicine.

As a Swedish public university, Karolinska receives the majority of its funding from the Swedish government through research grants and educational appropriations. The endowment and foundation assets serve a supplementary role, supporting research initiatives, student scholarships, faculty development, and strategic priorities that may not be fully covered by government funding.

The institution’s investment philosophy reflects Scandinavian institutional practices, emphasizing prudent risk management, diversification, and long-term capital preservation. Approximately 20% of endowment and foundation assets are allocated to alternative investments, including private equity, venture capital, and real estate. The remaining portfolio is diversified across Swedish and international equities, fixed income, and other liquid asset classes.

The endowment’s relatively conservative alternatives allocation reflects the different role that endowment assets play in the Nordic university funding model compared to the American system, where endowments are often the largest single source of university revenue.

Private Markets Approach

Karolinska’s private markets exposure is focused and targeted, reflecting the institution’s moderate alternatives allocation and its strong connection to the life sciences and healthcare sectors.

In private equity, Karolinska commits selectively to managers with strategies and track records aligned with the institution’s risk-return objectives. The endowment’s private equity commitments include both Nordic and international managers, with a preference for strategies demonstrating disciplined capital deployment and consistent returns.

The venture capital allocation benefits from Karolinska’s position at the center of Stockholm’s biotech and life sciences ecosystem. Sweden has produced a significant number of pharmaceutical and biotech companies, and the Karolinska Institute’s research output generates ongoing opportunities for technology commercialization and startup formation. The endowment’s VC exposure targets managers with expertise in healthcare, biotechnology, and life sciences, including those connected to the Nordic innovation ecosystem.

Real estate investments provide portfolio diversification and income generation through exposure to Nordic and international property markets.

The institution’s alternatives program is smaller in scale than those of major American or British university endowments, reflecting both the overall endowment size and the Scandinavian investment culture that emphasizes capital preservation alongside growth.

For fund managers seeking to work with the Karolinska Institute, the institution evaluates managers on strategy quality, team depth, alignment of interests, and track record. Managers with healthcare, biotech, or life sciences expertise may find particular alignment with the institution’s mission and investment interests. Referrals from trusted advisors, the Nordic institutional investor network, and the European LP community are the most effective paths to engagement.